在治疗真菌性脓胸患者时，两性霉素 B 胸腔内灌注后的药代动力学研究。
Pharmacokinetics of anidulafungin in pleural fluid during the treatment of a patient with Candida empyema.
机构信息
NIH Clinical Center, Pharmacy Department, National Heart Lung and Blood Instititute, Bethesda, MD, USA.
出版信息
Antimicrob Agents Chemother. 2011 May;55(5):2478-80. doi: 10.1128/AAC.01560-10. Epub 2011 Mar 14.
Abstract
Candida empyema is a serious complication of disseminated candidiasis. However, little is known about the intrapleural pharmacokinetics of echinocandins. We report the penetration of anidulafungin into the pleural fluid of a patient with Candida tropicalis empyema. The anidulafungin ratio for the area under the concentration-time curve from 0 h to the last measurement between pleural fluid and serum values was only 0.125 (12.5%), with pleural fluid concentrations ranging between 0.67 and 0.88 μg/ml.
摘要
念珠菌性脓胸是播散性念珠菌病的严重并发症。然而，关于棘白菌素类药物在胸腔内的药代动力学知之甚少。我们报告了 1 例热带念珠菌性脓胸患者中阿尼芬净在胸腔液中的渗透情况。胸腔液与血清值之间的 0 小时至最后测量时间的浓度-时间曲线下面积比值仅为 0.125（12.5%），胸腔液浓度范围为 0.67 至 0.88μg/ml。
相似文献
1
Pharmacokinetics of anidulafungin in pleural fluid during the treatment of a patient with Candida empyema.在治疗真菌性脓胸患者时，两性霉素 B 胸腔内灌注后的药代动力学研究。
Antimicrob Agents Chemother. 2011 May;55(5):2478-80. doi: 10.1128/AAC.01560-10. Epub 2011 Mar 14.
2
Anidulafungin Pharmacokinetics in Ascites Fluid and Pleural Effusion of Critically Ill Patients.棘白菌素类药物在重症患者腹水和胸腔积液中的药代动力学。
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.02326-17. Print 2018 Apr.
3
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.阿尼芬净在中性粒细胞减少小鼠念珠菌病模型中的体内药效学特征
Antimicrob Agents Chemother. 2008 Feb;52(2):539-50. doi: 10.1128/AAC.01061-07. Epub 2007 Dec 10.
4
Pharmacokinetics of echinocandins in suspected candida peritonitis: A potential risk for resistance.棘白菌素类药物在疑似念珠菌性腹膜炎中的药代动力学：耐药的潜在风险。
Int J Infect Dis. 2020 Dec;101:24-28. doi: 10.1016/j.ijid.2020.09.019. Epub 2020 Sep 13.
5
Echinocandin antifungal drugs in fungal infections: a comparison.棘白菌素类抗真菌药物治疗真菌感染：比较。
Drugs. 2011 Jan 1;71(1):11-41. doi: 10.2165/11585270-000000000-00000.
6
Pharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection.棘白菌素类药物治疗实验性眼内白色念珠菌感染的药代动力学和药效学研究：棘白菌素类药物治疗潜在致盲性感染的应用价值。
Antimicrob Agents Chemother. 2013 Jan;57(1):281-8. doi: 10.1128/AAC.01387-12. Epub 2012 Oct 31.
7
Pharmacokinetic study of anidulafungin in ICU patients with intra-abdominal candidiasis.阿尼芬净在腹腔内念珠菌病重症监护病房患者中的药代动力学研究。
J Antimicrob Chemother. 2017 May 1;72(5):1429-1432. doi: 10.1093/jac/dkw568.
8
Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis.棘白菌素类药物在合并念珠菌性腹膜炎危重症患者中的药代动力学。
Int J Infect Dis. 2019 Sep;86:142-146. doi: 10.1016/j.ijid.2019.07.008. Epub 2019 Jul 19.
9
Management of Aspergillus pleural empyema with combined systemic and intrapleural antifungal therapy in a pediatric patient: Case report.儿童患者合并全身和胸膜内抗真菌治疗曲霉性脓胸的管理：病例报告。
J Infect Public Health. 2018 Mar-Apr;11(2):280-282. doi: 10.1016/j.jiph.2017.04.003. Epub 2017 May 22.
10
Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients.评估基于药代动力学/药效学分析的棘白菌素方案对儿科患者念珠菌属的疗效。
Int J Antimicrob Agents. 2015 Dec;46(6):631-41. doi: 10.1016/j.ijantimicag.2015.08.009. Epub 2015 Sep 21.
引用本文的文献
1
In Vivo Efficacy of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Clades in a Neutropenic Mouse Bloodstream Infection Model.瑞扎芬净、阿尼芬净、卡泊芬净和米卡芬净在中性粒细胞减少小鼠血流感染模型中对四个进化枝的体内疗效。
J Fungi (Basel). 2024 Aug 29;10(9):617. doi: 10.3390/jof10090617.
2
Application and evaluation of topical amphotericin B for the treatment of respiratory fungal infections.局部用两性霉素B治疗呼吸道真菌感染的应用与评价
BMC Infect Dis. 2024 Apr 24;24(1):439. doi: 10.1186/s12879-024-09342-9.
3
The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective.新型抗真菌药物在念珠菌病治疗中的作用：临床视角。
Mycopathologia. 2023 Dec;188(6):937-948. doi: 10.1007/s11046-023-00759-5. Epub 2023 Jul 20.
4
An Unusual Case of Candida albicans Empyema in Patient With Gastric Cancer and Colon Metastasis.一例罕见的白色念珠菌性脓胸病例：患者患有胃癌并伴有结肠转移
Cureus. 2023 Jan 20;15(1):e34023. doi: 10.7759/cureus.34023. eCollection 2023 Jan.
5
The outcomes of thoracoscopic decortication between fungal empyema and bacterial empyema.胸腔镜下肺切除治疗真菌性脓胸和细菌性脓胸的疗效比较。
BMC Infect Dis. 2023 Jan 6;23(1):8. doi: 10.1186/s12879-022-07978-z.
6
Empyema Thoracis-A Post-COVID-19 Complication.脓胸——一种新冠后遗症
J Fungi (Basel). 2022 Aug 30;8(9):923. doi: 10.3390/jof8090923.
7
A Case Report of -Associated Empyema Treated With Intravenous Injection and Local Thoracic Irrigation of Amphotericin B Plus Medical Thoracoscopy.一例 -相关脓胸经两性霉素 B 静脉注射和局部胸腔灌洗联合内科胸腔镜治疗。
Front Public Health. 2022 Jul 6;10:914529. doi: 10.3389/fpubh.2022.914529. eCollection 2022.
8
Empyema Thoracis at Two Academic Medical Centers: New Insights Into Treatment and Outcomes.两家学术性医学中心的脓胸：治疗与结局的新见解
Open Forum Infect Dis. 2021 Apr 17;8(4):ofaa656. doi: 10.1093/ofid/ofaa656. eCollection 2021 Apr.
9
Comparison of Killing Activity of Micafungin Against Six Candida Species Isolated from Peritoneal and Pleural Cavities in RPMI-1640, 10 and 30% Serum.在 RPMI-1640 培养基、10% 和 30% 血清中比较米卡芬净对来源于腹腔和胸腔的六种念珠菌的杀菌活性。
Mycopathologia. 2018 Dec;183(6):905-912. doi: 10.1007/s11046-018-0302-5. Epub 2018 Oct 31.
10
Anidulafungin Pharmacokinetics in Ascites Fluid and Pleural Effusion of Critically Ill Patients.棘白菌素类药物在重症患者腹水和胸腔积液中的药代动力学。
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.02326-17. Print 2018 Apr.
本文引用的文献
1
A case of Aspergillus empyema successfully treated with combination therapy of voriconazole and micafungin: excellent penetration of voriconazole and micafungin into pleural fluid.伏立康唑与米卡芬净联合治疗成功治愈1例曲霉菌性脓胸：伏立康唑和米卡芬净在胸腔积液中具有良好的渗透性。
Intern Med. 2010;49(12):1163-9. doi: 10.2169/internalmedicine.49.2860. Epub 2010 Jun 15.
2
Pharmacokinetics of liposomal amphotericin B in pleural fluid.脂质体两性霉素 B 在胸腔积液中的药代动力学。
Antimicrob Agents Chemother. 2010 Apr;54(4):1633-5. doi: 10.1128/AAC.01438-09. Epub 2010 Jan 19.
3
Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.健康成年人静脉注射伏立康唑和阿尼芬净联合用药的支气管肺部分布。
Antimicrob Agents Chemother. 2009 Dec;53(12):5102-7. doi: 10.1128/AAC.01042-09. Epub 2009 Sep 21.
4
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.念珠菌病管理临床实践指南：美国传染病学会2009年更新版
Clin Infect Dis. 2009 Mar 1;48(5):503-35. doi: 10.1086/596757.
5
Penetration of amphotericin B lipid formulations into pleural effusion.两性霉素B脂质制剂在胸腔积液中的渗透情况。
Antimicrob Agents Chemother. 2007 Nov;51(11):4211-3. doi: 10.1128/AAC.01087-07. Epub 2007 Sep 4.
6
Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences.棘白菌素对念珠菌属的体外矛盾效应：棘白菌素特异性及念珠菌属相关差异的证据
Antimicrob Agents Chemother. 2007 Jun;51(6):2257-9. doi: 10.1128/AAC.00095-07. Epub 2007 Apr 16.
7
Pericardial and pleural diffusion of voriconazole during disseminated invasive aspergillosis: report of a case with successful outcome.伏立康唑在播散性侵袭性曲霉病中的心包和胸膜扩散：一例成功治愈病例报告
Intensive Care Med. 2006 Jun;32(6):939-40. doi: 10.1007/s00134-006-0113-x. Epub 2006 Mar 11.
8
Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.伏立康唑与阿尼芬净联合使用的安全性和药代动力学。
J Clin Pharmacol. 2005 Dec;45(12):1373-82. doi: 10.1177/0091270005281234.
9
Pleural diffusion of voriconazole in a patient with Aspergillus fumigatus empyema thoracis.伏立康唑在一名烟曲霉性脓胸患者中的胸膜扩散情况。
Antimicrob Agents Chemother. 2004 Mar;48(3):1065. doi: 10.1128/AAC.48.3.1065.2004.
10
Echinocandin antifungal drugs.棘白菌素类抗真菌药物。
Lancet. 2003 Oct 4;362(9390):1142-51. doi: 10.1016/S0140-6736(03)14472-8.
Zotero 插件